News

Date Title View
Toggle Summary Aerie Pharmaceuticals Announces Appointment of New Members of its Commercialization Team
IRVINE, Calif. --(BUSINESS WIRE)--Sep. 29, 2017-- Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of glaucoma and other diseases of the eye, today announced
View HTML
Toggle Summary Aerie Pharmaceuticals Announces Appointment of Sheila Elliott, PharmD, as Western Regional Director of Medical Science Liaisons
IRVINE, Calif. --(BUSINESS WIRE)--Sep. 25, 2017-- Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of glaucoma and other diseases of the eye, today announced
View HTML
Toggle Summary Aerie Pharmaceuticals Announces FDA Advisory Committee Meeting for Rhopressa™ (netarsudil ophthalmic solution) 0.02%
Meeting Scheduled for October 13, 2017 IRVINE , Calif.--(BUSINESS WIRE)--Sep. 20, 2017-- Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) (Aerie or the Company), a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of first-in-class therapies for the
View HTML
Toggle Summary Aerie Pharmaceuticals Announces Appointment of Tori Arens as Vice President of Drug Product Manufacturing and Eric Carlson, Ph.D. as Vice President of Research and Development
IRVINE, Calif. --(BUSINESS WIRE)--Sep. 19, 2017-- Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of open-angle glaucoma and other diseases of the eye, today
View HTML
Toggle Summary Aerie Pharmaceuticals to Present at Two Investor Conferences in September
IRVINE, Calif. --(BUSINESS WIRE)--Sep. 6, 2017-- Aerie Pharmaceuticals, Inc. (Nasdaq:AERI), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of glaucoma and other diseases of the eye, today announced
View HTML
Toggle Summary Aerie Pharmaceuticals Initiates Mercury 3 Clinical Trial of Roclatan™ (netarsudil/latanoprost ophthalmic solution) 0.02%/0.005%
First Patient Dosed in Clinical Trial Designed for European Market IRVINE , Calif.--(BUSINESS WIRE)--Sep. 6, 2017-- Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) (Aerie or the Company), a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of
View HTML
Toggle Summary Aerie Pharmaceuticals Announces Appointment of Deanne Melloy as Vice President of Marketing and Norbert Lowe as Regional Sales Director
IRVINE, Calif. --(BUSINESS WIRE)--Aug. 28, 2017-- Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of glaucoma and other diseases of the eye, today announced
View HTML
Toggle Summary Aerie Pharmaceuticals Announces Appointment of Isabel Moredo, PharmD, as Eastern Regional Director of Medical Science Liaisons
IRVINE, Calif. --(BUSINESS WIRE)-- Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of glaucoma and other diseases of the eye, today announced the appointment
View HTML
Toggle Summary Aerie Pharmaceuticals Comments on Notification from Contract Manufacturer
IRVINE , Calif.--(BUSINESS WIRE)-- Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) (Aerie or the Company), a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of first-in-class therapies for the treatment of patients with glaucoma and other diseases of the
View HTML
Toggle Summary Aerie Pharmaceuticals to Present at the Canaccord Genuity Growth Conference
IRVINE, Calif. --(BUSINESS WIRE)-- Aerie Pharmaceuticals, Inc. (Nasdaq:AERI), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of glaucoma and other diseases of the eye, today announced that Vicente
View HTML